Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Front Oncol
मुख्य लेखकों: Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2019
विषय:
Oncology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://ncbi.nlm.nih.gov/pubmed/31165048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन